Abstract
Aim:
To analyze the efficacy of PD-1 blockade combined with RetroNectin®-activated cytokine-induced killer (R-CIK) cells in preheavily treated advanced non-small-cell lung cancer (NSCLC).
Methods:
We retrospectively analyzed patients with advanced NSCLC who received PD-1 blockade combined with R-CIK cells whose treatments failed at least two regimens.
Results:
The median number of previous treatment regimens was three (range: 2-7). Partial remission was achieved in two patients, stable disease in four patients and one patient experienced progressive disease. The median time-to-progression was 4.8 months.
Conclusion:
PD-1 blockade combined with R-CIK cells is safe and effective in patients with advanced NSCLC who have failed at least two treatment regimens.
Keywords:
adoptive cell immunotherapy; anti-PD-1; carcinoma; combination; non-small-cell lung.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Cells, Cultured
-
Combined Modality Therapy
-
Cytokine-Induced Killer Cells / immunology*
-
Cytokine-Induced Killer Cells / transplantation
-
Female
-
Fibronectins / immunology
-
Humans
-
Immunotherapy, Adoptive / methods*
-
Lung Neoplasms / immunology
-
Lung Neoplasms / mortality
-
Lung Neoplasms / therapy*
-
Male
-
Middle Aged
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Nivolumab / therapeutic use*
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Recombinant Proteins / immunology
-
Retrospective Studies
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Fibronectins
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Recombinant Proteins
-
retronectin
-
Nivolumab
-
pembrolizumab